SAN DIEGO, Sept. 13, 2017 /PRNewswire/ — Biotech Holdings, a clinical stage company leveraging the microbiome to enhance efficacy of stem cells announced today the recruitment of Peter C Farrell, PhD, DSc, AM to its Advisory Board. 

Dr. Farrell is the founder and chairman of the board of ResMed, a NYSE traded company that changes lives with medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. Dr. Farrell also is a board member of NuVasive, Inc., a NASDAQ-listed company which develops and markets products for the surgical treatment of spine disorders. Dr. Farrell is on the board of trustees of The Scripps Research Institute, as well as a member of the MIT Dean of Engineering Advisory Board and the Executive Council of the Division of Sleep Medicine at Harvard Medical School, of which he was chair during 2011-2013.

“It is an honor that I welcome Dr. Farrell to the Biotech Holdings Advisory Board. Dr. Farrell possesses the rare gift of being very business savvy while also being an acknowledged and well published scientist/engineer. It is rare to find one individual with both traits at such a high level,” said Thomas Ichim, Ph.D, President and CEO of Biotech Holdings.  “I look forward to Dr. Farrell’s advice and insight as Biotech Holdings continues on its path to developing microbiome-augmented stem cell therapeutics.”

Biotech Holdings is currently developing ProCell, an autologous bone marrow stem cell therapy augmented with healthy microbiome-derived compounds which has shown promise in animal models of critical limb ischemia, a condition that causes over 250,000 amputations per year in the USA.  The Company also reported preliminary results in a 3 patient investigator initiated study. 

“I have always enjoyed championing new and potentially revolutionary concepts. Biotech Holdings is, to my knowledge, the first entity to develop therapeutic applications of the microbiome to regenerative medicine. I am delighted to work with Biotech in this exciting new endeavor,” said Dr. Farrell.

About Biotech Holdings

Biotech Holdings was founded on technologies and patents developed by Dr. Amit Patel and Dr. Thomas Ichim focused on identifying interactions between gut bacteria (microbiome) and stem cells.  The Company has identified several bacterially derived compounds that enhance stem cell activity and is applying these to chronic diseases associated with circulation deficiencies.  Initial therapeutic indications the company is targeting are: Critical Limb Ischemia and Ischemic Heart Failure.  The Company has 10 patent applications filed covering stem cell modulation, augmentation, and differentiation by bacterial compounds.


Thomas E Ichim, Ph.D
President and Chief Executive Officer
BioTech Holdings
9255 Towne Centre Drive, #450
San Diego, CA 92121 
858 353 4303
Twitter: @biotechholdings

View original content with multimedia:

SOURCE Biotech Holdings